Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.

Abstract: The invention includes an isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell. The invention also includes a transport construct in which a transport peptide is linked to a cargo moiety to be delivered into a cell. The invention further includes a method of delivering a transport construct into and/or to a cell.

Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell, is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.

Abstract: An approach is provided for determining disaster recovery capacity. A simulation hypervisor receives streaming metric data, which represents the current production workload of a primary site, from the primary site. The metric data is combined with production data of the backup site by the simulation hypervisor to simulate a recovery event. Using data from the simulating, disaster recovery planning can be performed.

Abstract: The invention includes an isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell. The invention also includes a transport construct in which a transport peptide is linked to a cargo moiety to be delivered into a cell. The invention further includes a method of delivering a transport construct into and/or to a cell.

Abstract: An approach is provided for determining disaster recovery capacity. A simulation hypervisor receives streaming metric data, which represents the current production workload of a primary site, from the primary site. The metric data is combined with production data of the backup site by the simulation hypervisor to simulate a recovery event. Using data from the simulating, disaster recovery planning can be performed.

Abstract: An approach is provided for determining disaster recovery capacity. A simulation hypervisor receives streaming metric data, which represents the current production workload of a primary site, from the primary site. The metric data is combined with production data of the backup site by the simulation hypervisor to simulate a recovery event. Using data from the simulating, disaster recovery planning can be performed.

Abstract: An approach is provided for internet protocol (IP) address failover. An application on a primary site is assigned a private IP address. This private IP address is accessible within a local network. This private IP address is mapped to a public IP address, which is accessible to users outside the local network. The application is then replicated to a backup site with the same private IP address used to access it on the primary site. In case of a disaster recover event on the primary site, the replicated application can be accessed on the backup site by way of the public IP address.

Abstract: Aspects of the present invention provide a solution for implementing disaster recovery for an application. A subscription backup site for the application is selected from among a plurality of sites. The site that is selected will have a virtual space that is able to accommodate the workload requirements for the application. The application is deflated on the site in such as way as to operate in a dormant state. In the dormant state, the application has a small fraction of its required resources allocated to it. Thereafter, when disaster recovery is needed, the application can be inflated on the subscription backup site by allocating resources to enable the application to execute on the subscription backup site.

Abstract: An approach is provided for internet protocol (IP) address failover. An application on a primary site is assigned a private IP address. This private IP address is accessible within a local network. This private IP address is mapped to a public IP address, which is accessible to users outside the local network. The application is then replicated to a backup site with the same private IP address used to access it on the primary site. In case of a disaster recover event on the primary site, the replicated application can be accessed on the backup site by way of the public IP address.

Abstract: An approach is provided for determining disaster recovery capacity. A simulation hypervisor receives streaming metric data, which represents the current production workload of a primary site, from the primary site. The metric data is combined with production data of the backup site by the simulation hypervisor to simulate a recovery event. Using data from the simulating, disaster recovery planning can be performed.

Abstract: Aspects of the present invention provide a solution for implementing disaster recovery for an application. A subscription backup site for the application is selected from among a plurality of sites. The site that is selected will have a virtual space that is able to accommodate the workload requirements for the application. The application is deflated on the site in such as way as to operate in a dormant state. In the dormant state, the application has a small fraction of its required resources allocated to it. Thereafter, when disaster recovery is needed, the application can be inflated on the subscription backup site by allocating resources to enable the application to execute on the subscription backup site.

Abstract: Methods are provided for treating patients with cardiovascular disease, including heart disease and peripheral vascular disease. The preferred methods of the present invention involve in vivo delivery of genes, encoding angiogenic proteins or peptides, to the myocardium or to peripheral ischemic tissue, by introduction of a vector containing the gene into a blood vessel supplying the heart or into a peripheral ischemic tissue.

Abstract: The invention describes isolated transport peptides, which cross the cell membrane of a cell and/or home to a target cell. The invention also describes a transport complex in which a transport peptide is linked to a cargo moiety to be delivered into/to a cell. Methods are disclosed describing delivery of a transport complex into and/or to a cell. Vectors and host cells comprising transport peptides and transport complexes are also described, as well as pharmaceutical compositions including transport complexes of the present invention.

Abstract: The transgene-inserted replication-deficit adenoviral vector is effectively used in in vivo gene therapy for myocardial ischemia in a protective way, by a single intracoronary injection directly conducted deeply in the lumen of the coronary arteries in an amount sufficient for transfecting all cell types in the affected region, including cardiac myocytes.

Abstract: Methods are provided for treating patients with cardiovascular disease, including heart disease and peripheral vascular disease. The preferred methods of the present invention involve in vivo delivery of genes, encoding angiogenic proteins or peptides, to the myocardium or to peripheral ischemic tissue, by introduction of a vector containing the gene into a blood vessel supplying the heart or into a peripheral ischemic tissue.

Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.

Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.

Abstract: The transgene-inserted replication-deficit adenovirus vector is effectively used in in vivo gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.